IP Library Granted Patent US 11,648,267
Granted Patent B2
US 11,648,267 · App. 16/026,722 · Granted May 16, 2023

Methods and compositions for gene inactivation

Inventors: Dale Ando (Richmond, CA); Michael C. Holmes (Richmond, CA); Gary Ka Leong Lee (Richmond, CA)
Assignee: Sangamo Therapeutics, Inc.
A61K35/17A61K35/12C07K14/47C07K14/4703C12N5/10C12N9/22A61K38/00A61K48/00A61K2035/124A61P31/18C12N15/86C12N2710/10343C12N2710/10345
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,648,267
App. No.
16/026,722
Granted
May 16, 2023
Kind
B2
Abstract

Disclosed herein are methods and compositions for inactivating CCR-5 genes, using zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding ZFNs, vectors comprising polynucleotides encoding ZFNs, such as adenovirus (Ad) vectors, and cells comprising polynucleotides encoding ZFNs and/or cells comprising ZFNs are also provided.

Claims (17)

1. A population of genetically modified human CD4+T cells or hematopoietic stem cells (HSCs) comprising

(a) a nuclease comprising a single pair of zinc finger nucleases (ZFNs), each zinc finger nuclease comprising a DNA-binding domain that binds to a target site in an endogenous CCR5 gene in the mammalian cell, wherein the DNA-binding domain comprises four zinc finger recognition regions ordered F1 to F4 from N-terminus to C-terminus, and further wherein the zinc finger DNA-binding domains comprise recognition regions selected from the group consisting of:

(i) F1: DRSNLSR (SEQ ID NO:2);

F2: ISSNLNS (SEQ ID NO:5);

F3: RSDNLAR (SEQ ID NO:4); and

F4: TSANLSR (SEQ ID NO:3) or F4: NRDNLSR (SEQ ID NO:7) and

(ii)

F1: RSDNLSN (SEQ ID NO:14);

F2: QNANRIT (SEQ ID NO:11);

F3: RSDVLSE (SEQ ID NO:12); and

F4: QRNHRTT (SEQ ID NO:13) such that expression of the endogenous CCR5 gene is disrupted following cleavage of the endogenous CCR5 gene at one location by the pair of ZFNs and cell-surface expression of the CCR5 receptor is prevented;

(b) a disrupted MHC receptor gene such that the genetically modified CD4+T cell or HSC exhibits diminished or abolished immunological identity.

2. A method for targeted integration of an exogenous sequence into an endogenous CCR5 gene in a cell, the method comprising:

providing a population of cells according to claim 1 under conditions such that the CCR5 gene is cleaved in the presence of the exogenous sequence and the exogenous sequence is integrated into the cleaved CCR5 gene.

3. A cell produced from a population of cells according to claim 1 .

4. A method of treating a subject with CCR5-tropic HIV, the method comprising administering a cell according to claim 3 .

5. A method of treating a subject with CCR5-tropic HIV, the method comprising administering a population of cells according to claim 1 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 22, 2022
From: ANDO, DALE; HOLMES, MICHAEL C.; LEE, GARY KA LEONG
To: SANGAMO BIOSCIENCES, INC.
Reel/Frame 060596/0087 →
CHANGE OF NAME Recorded Jul 22, 2022
From: SANGAMO BIOSCIENCES, INC.
To: SANGAMO THERAPEUTICS, INC.
Reel/Frame 060831/0103 →
Continuity (8)
Continuation 15220914 · Jul 27, 2016
Continuation 14054042 · Oct 15, 2013
Continuation 13068348 · May 9, 2011
Continuation 11805707 · May 23, 2007
Provisional Application 60808501 · May 25, 2006
Provisional Application 60847269 · Sep 26, 2006
Provisional Application 60926911 · Apr 30, 2007
Related Publication 20180312826A1 · Nov 1, 2018